Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

• Status: Not yet recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Treatments: abobotulinumtoxinA; Botulinum Toxins, Type A; incobotulinumtoxinA

Criteria

Inclusion Criteria:

• Female

• 30-65 years of age

• Interested in glabellar injections to reduce rhytids and facial strain

• Participants must sign the informed consent form

Exclusion Criteria:

• Females under 30 or above 65 years of age

• Males

• Those who have received glabellar injections for rhytids <12 months

• Underwent cosmetic surgical procedure above the malar region

• Those with a condition that affects facial expression, such as prior stroke